2009
Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience
Dankwah-Quansah M, Gutin P, Bilsky M, Huse J, Rosenblum M, Abrey L, DeAngelis L, Omuro A. Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Journal Of Clinical Oncology 2009, 27: e13011-e13011. DOI: 10.1200/jco.2009.27.15_suppl.e13011.Peer-Reviewed Original ResearchIntracranial hemangiopericytomaStable diseaseDisease courseMemorial Sloan-Kettering Cancer Center experienceMedian progression-free survivalRare primary brain tumorsTargeted therapy eraMedian overall survivalProgression-free survivalCancer Center experienceOptimal clinical managementPatterns of carePrimary brain tumorsEfficacy of chemotherapyAdditional radiotherapyMedian KPSTherapy eraAdjuvant radiotherapySalvage treatmentCytotoxic chemotherapyOverall survivalSurgical resectionCenter experienceMedian ageRetrospective review
2008
What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas?
Omuro AM, Delattre JY. What is the place of bevacizumab and irinotecan in the treatment of glioblastoma and other malignant gliomas? Current Opinion In Neurology 2008, 21: 717-719. PMID: 18989118, DOI: 10.1097/wco.0b013e3283184625.Peer-Reviewed Original ResearchConceptsMalignant gliomasOverall survivalClinical trialsProspective phase II trialPlace of bevacizumabProgression-free survivalPhase II trialNew treatment strategiesHigh response rateTreatment of glioblastomaII trialRecurrent diseaseSalvage treatmentCytotoxic chemotherapyMost patientsConventional radiographic methodsDisease progressionHistorical controlsSurvival resultsRadiographic criteriaTreatment strategiesBevacizumabResponse rateNew treatmentsGliomas